Ipamorelin

Research Use Only: This page is for research and educational purposes only. It does not provide medical advice, treatment instructions, or guaranteed outcome claims.

What Is Ipamorelin?

If your query is what is ipamorelin, the practical answer is: ipamorelin is a synthetic growth hormone secretagogue (GHS) — a pentapeptide that stimulates growth hormone release by activating the ghrelin receptor (GHS-R1a) on pituitary somatotroph cells. What distinguishes ipamorelin from other GH secretagogues like GHRP-2 and GHRP-6 is its selectivity: it stimulates GH release without significantly elevating cortisol, ACTH, prolactin, or aldosterone.[1][2]

Raun et al. (1998) described ipamorelin as “the first selective growth hormone secretagogue” in European Journal of Endocrinology, documenting its ability to produce dose-dependent GH release comparable to GHRP-6 while avoiding the broader hormonal perturbations seen with earlier GH secretagogues.[1]

This selectivity profile is ipamorelin’s defining characteristic. While all GH secretagogues activate the ghrelin receptor to stimulate GH release, most also produce varying degrees of appetite stimulation, cortisol elevation, and aldosterone increases. Ipamorelin peptide achieves GH stimulation with minimal off-target hormonal effects, making it the cleanest GH secretagogue in terms of selectivity.[1][2][3]

For context within the GH-axis peptide class, ipamorelin works via a completely different receptor pathway than GHRH analogs like Sermorelin, CJC-1295, and Tesamorelin. While those compounds stimulate GH through the GHRH receptor, ipamorelin acts through the ghrelin/GHS receptor — making them mechanistically complementary rather than competitive.

Compound Profile

What Does Ipamorelin Actually Do?

Ipamorelin activates the ghrelin receptor (GHS-R1a) on anterior pituitary somatotroph cells, triggering pulsatile growth hormone release. The practical result is elevated GH and downstream IGF-1 levels achieved through a pathway that complements, rather than replaces, the body’s endogenous GHRH signalling.[1][2]

Key findings from published research:

• Selective GH release (Raun 1998): the foundational study demonstrated that ipamorelin produces dose-dependent GH release comparable to GHRP-6 in both in vitro pituitary cell cultures and in vivo animal models, but without affecting cortisol, ACTH, prolactin, or aldosterone levels — a selectivity advantage over all previously characterised GH secretagogues. Published in European Journal of Endocrinology.[1]
• Mechanistic distinction from GHRH (Ahnfelt-Rønne 2001): confirmed that GH-releasing peptides including ipamorelin act through the ghrelin/GHS receptor pathway rather than the GHRH receptor, establishing the mechanistic basis for dual-pathway GH stimulation when combined with GHRH analogs.[2]
• Bone growth stimulation (Johansen 1999): demonstrated that ipamorelin induces longitudinal bone growth in rats via GH-mediated IGF-1 elevation, supporting the connection between GH secretagogue-driven GH release and tissue-level anabolic effects.[4]
• Bone mineral preservation (Andersen 2001): showed ipamorelin counteracts glucocorticoid-induced decreases in bone formation in adult rats — evidence that GHS-mediated GH elevation can protect against catabolic bone loss.[5]
• Bone mineral content increase (Svensson 2000): ipamorelin and GHRP-6 both increased bone mineral content in adult female rats, demonstrating skeletal benefit from GH secretagogue stimulation.[6]

How Ipamorelin Works

Ipamorelin’s mechanism operates through the ghrelin receptor pathway — pharmacologically distinct from the GHRH receptor pathway used by sermorelin, CJC-1295, and tesamorelin.[1][2]

• GHS-R1a activation: ipamorelin binds the growth hormone secretagogue receptor type 1a (GHS-R1a, also known as the ghrelin receptor) on pituitary somatotroph cells. This triggers intracellular calcium signalling and IP3/DAG pathways, leading to GH granule release.[1][2]
• Selectivity mechanism: unlike GHRP-2 and GHRP-6, ipamorelin does not significantly activate other pituitary hormone pathways. It does not elevate ACTH (which drives cortisol), prolactin, or aldosterone at GH-stimulating doses. This selectivity is attributed to its specific receptor binding profile — strong GHS-R1a affinity without meaningful activation of other receptor subtypes.[1]
• Complementary to GHRH pathway: GH release from somatotrophs is regulated by two opposing signals: GHRH (stimulatory) and somatostatin (inhibitory). GH secretagogues like ipamorelin work through a third, independent pathway (GHS-R1a), amplifying GH release even when GHRH signalling is moderate. This is why ipamorelin CJC-1295 combinations are frequently discussed — they stimulate GH through two separate receptor pathways simultaneously.[2][7]
• Pulsatile release preserved: ipamorelin triggers discrete GH pulses rather than continuous elevation, maintaining the body’s natural secretory rhythm and somatostatin-mediated feedback.[1][3]

The dual-pathway concept: when combined with a GHRH analog (CJC-1295 or sermorelin), ipamorelin provides GHS-R1a stimulation while the GHRH analog provides GHRH receptor stimulation. This dual input to the somatotroph cell is theorised to produce a synergistic GH response greater than either pathway alone — though formal head-to-head clinical trials of the combination are limited.[2][7][8]

Recovery and Sleep Context

Recovery and sleep is one of ipamorelin’s most practically relevant domains, through its role in augmenting nocturnal GH pulses.

• GH-sleep relationship: the largest natural GH pulse occurs during slow-wave (deep) sleep. Jessup et al. (2004) demonstrated the specific mechanistic link between GH-releasing pathways and nocturnal GH secretion. GH secretagogue stimulation amplifies this natural pulse, supporting tissue repair and protein synthesis during sleep.[9]
• Recovery quality: elevated nocturnal GH supports glycogen replenishment, tissue repair, and immune function during sleep. Ipamorelin users most consistently report improved recovery quality upon waking and better readiness between training sessions.
• Clean sleep augmentation: ipamorelin’s selectivity advantage is relevant here — it doesn’t elevate cortisol (which would disrupt sleep architecture) or stimulate appetite significantly (which would be counterproductive at bedtime). This makes it the cleanest GH secretagogue for evening/bedtime use targeting sleep-linked recovery.[1][3]

Practical interpretation: ipamorelin’s value for recovery is through GH-mediated physiological processes during sleep, not as a sleep aid per se. Track recovery quality and training readiness over 4+ week blocks rather than expecting immediate single-night effects.

Body Composition and Muscle Growth Context

Muscle growth and body composition relevance for ipamorelin operates through the GH/IGF-1 axis. The evidence base is primarily preclinical and mechanistic, with supporting context from GH secretagogue class reviews.[1][7][8]

• GH-driven anabolic signalling: ipamorelin-stimulated GH release drives hepatic IGF-1 production, which supports protein synthesis, nitrogen retention, and muscle repair. The effect is indirect — ipamorelin stimulates GH, which stimulates IGF-1, which supports anabolic processes.[1]
• Body composition management: Sinha et al. (2020) reviewed GH secretagogues as body composition tools in hypogonadal men, noting their role in supporting lean mass maintenance and fat reduction alongside other interventions.[8]
• Bone health support: Johansen (1999) and Andersen (2001) demonstrated that ipamorelin promotes bone growth and counteracts glucocorticoid-induced bone loss in animal models — supporting the broader musculoskeletal benefit of GH secretagogue-mediated GH elevation.[4][5]
• Recovery-driven training adaptation: the primary muscle growth mechanism is through improved recovery between training sessions, enabling higher training consistency, volume tolerance, and adaptation over time.

Honest assessment: ipamorelin is a recovery and hormonal environment support compound, not a direct muscle builder. The ipamorelin benefits for body composition are most visible when training, nutrition, and sleep fundamentals are already well-established. Expect gradual improvements in recovery quality and body composition trends over weeks, not rapid transformation.

Fat Loss and Body Recomp Context

Fat loss and body recomposition with ipamorelin operates through GH’s lipolytic effects. Growth hormone promotes fatty acid mobilisation from adipose tissue and shifts substrate utilisation toward fat oxidation.

• GH-driven lipolysis: elevated GH levels promote the breakdown and mobilisation of stored triglycerides. The effect is gradual and most visible in body composition ratios (lean mass to fat mass) rather than dramatic scale weight changes.[7][8]
• Cortisol advantage: unlike GHRP-2 and GHRP-6, ipamorelin does not elevate cortisol — a catabolic hormone that promotes fat storage (particularly visceral fat) and muscle breakdown. This selectivity makes ipamorelin theoretically more favourable for body recomposition goals.[1][3]
• Appetite neutrality: GHRP-6 and ghrelin itself strongly stimulate appetite, which can counteract fat loss efforts. Ipamorelin’s appetite effect is minimal, making it easier to maintain caloric targets during fat loss phases.[1]

Practical framing: ipamorelin supports fat loss through hormonal environment optimisation rather than direct metabolic acceleration. For dedicated fat loss, compounds like semaglutide or tirzepatide have dramatically stronger direct evidence. Ipamorelin’s role in fat loss is as a support compound within a broader strategy.

Hormonal Support Context

Testosterone and hormonal support with ipamorelin is indirect. Ipamorelin acts exclusively on the GH axis via GHS-R1a, not the HPG axis that governs testosterone production.[1][2]

However, adequate GH signalling supports the broader endocrine environment. Sinha et al. (2020) specifically positioned GH secretagogues as adjuncts in hypogonadal management — noting that optimising the GH axis supports body composition, recovery, and metabolic health, all of which contribute to overall hormonal wellbeing.[8]

Merriam et al. (2003) reviewed GH secretagogues in the context of normal aging, noting that somatopause compounds GH decline alongside other age-related endocrine changes. Addressing GH-axis decline may complement other interventions targeting the broader hormonal landscape.[7]

The honest framing: ipamorelin is a GH-axis compound with possible indirect hormonal environment benefits. For dedicated testosterone or hormonal support, it is best evaluated as part of a multi-modal approach rather than a standalone solution.

Ipamorelin CJC-1295 Combination

The ipamorelin CJC-1295 combination (search volume: 2,400+) is one of the most frequently searched pairings in the GH peptide space. The rationale is dual-pathway GH stimulation:

• Ipamorelin: activates GHS-R1a (ghrelin receptor pathway)
• CJC-1295: activates the GHRH receptor pathway

These are independent receptor systems on the same pituitary somatotroph cell. The theoretical basis for synergy is that stimulating both inputs simultaneously produces greater GH release than either alone — an effect documented for GHRH + GHS-R1a agonist combinations in neuroendocrine research.[2][7]

Important caveat: while the pharmacological rationale for synergy is sound, formal clinical trials specifically evaluating the ipamorelin + CJC-1295 combination in human subjects are limited. The combination is widely used based on mechanistic reasoning and individual compound evidence rather than dedicated combination trial data. See CJC-1295 vs Ipamorelin for the detailed comparison.

Ipamorelin Benefits

Ipamorelin benefits are best understood through the selectivity lens that distinguishes it from other GH secretagogues:

• Selective GH release: produces dose-dependent GH elevation without raising cortisol, ACTH, prolactin, or aldosterone — the cleanest GH secretagogue selectivity profile documented.[1]
• Recovery and sleep support: amplification of nocturnal GH pulses supports tissue repair, protein synthesis, and recovery quality during sleep.[9]
• Body composition support: GH-mediated improvements in lean mass maintenance and fat mobilisation, without the appetite stimulation that complicates fat loss with other GH secretagogues.[1][8]
• Bone health support: preclinical evidence demonstrates bone growth stimulation, increased bone mineral content, and protection against glucocorticoid-induced bone loss.[4][5][6]
• Minimal cortisol impact: does not elevate cortisol, preserving sleep architecture and avoiding the catabolic, fat-storing effects of cortisol elevation.[1][3]
• Minimal appetite stimulation: unlike GHRP-6 and ghrelin, ipamorelin does not significantly increase appetite — practical for maintaining caloric targets.[1]
• Complementary to GHRH analogs: works through a separate receptor pathway, enabling theoretical synergy with CJC-1295, sermorelin, or tesamorelin.[2][7]
• Good safety profile: Sigalos & Pastuszak (2018) reviewed GH secretagogues and confirmed acceptable safety profiles as a class.[3]

Ipamorelin Side Effects

For ipamorelin side effects intent, the safety profile benefits from the same selectivity that defines the compound’s advantages:

• Injection site reactions: redness, swelling, or discomfort at the injection site. The most commonly reported adverse effect.[3]
• Head rush or flushing: transient warmth or light-headedness shortly after injection, typically resolving within minutes.[3]
• Headache: occasional, usually mild and transient.[3]
• Water retention: mild fluid retention is possible with sustained GH elevation. Generally less pronounced than with exogenous GH.[3][10]
• Tingling or numbness: paraesthesia can occur with elevated GH/IGF-1 levels, typically mild.[3]

What ipamorelin does not typically cause (distinguishing it from other GH secretagogues):

• No significant cortisol elevation — unlike GHRP-2 and GHRP-6[1]
• No significant appetite stimulation — unlike GHRP-6 and ghrelin[1]
• No significant prolactin elevation — unlike GHRP-2[1]

Sigalos & Pastuszak (2018) reviewed GH secretagogues as a class and concluded they have acceptable safety profiles, though long-term surveillance data specifically for ipamorelin remains limited given its investigational status.[3]

Half-Life

Ipamorelin has an estimated half-life of approximately 2 hours after subcutaneous injection. This places it in the middle range for GH secretagogues — substantially longer than native ghrelin but shorter than modified GHRH analogs.[1][3]

For comparison across GH-axis peptides:

• Native ghrelin: approximately 30 minutes
• Sermorelin (GRF 1-29): approximately 10-20 minutes
• Ipamorelin: approximately 2 hours
• Tesamorelin: approximately 26 minutes
• CJC-1295 (no DAC): approximately 30 minutes
• CJC-1295 (with DAC): approximately 5-8 days

The ~2-hour half-life means ipamorelin produces a defined GH pulse followed by clearance — maintaining the pulsatile pattern that distinguishes secretagogue-mediated GH elevation from continuous exogenous GH. Evening/bedtime administration aligns the GH pulse with the natural nocturnal GH surge.[1][9]

Limits of Current Evidence

• No FDA approval. Ipamorelin has never been approved for any indication in any country. It remains investigational.[1][3]
• Evidence base is predominantly preclinical. The foundational selectivity data (Raun 1998) and the bone studies (Johansen 1999, Andersen 2001, Svensson 2000) are animal studies. Large-scale human clinical trials are lacking.[1][4][5][6]
• No dedicated human body composition trials. Unlike tesamorelin (which has JAMA and Lancet HIV RCTs), ipamorelin lacks published human trials specifically measuring body composition outcomes.
• Combination synergy is theoretical. The ipamorelin + CJC-1295 combination is widely used but lacks dedicated clinical trial evidence. The synergy rationale is based on dual-pathway receptor pharmacology, not direct combination studies.[2][7]
• Long-term safety data limited. The available safety data comes from relatively short-term preclinical studies and the GH secretagogue class review. Multi-year human safety data is not available.[3]
• GH secretagogue tachyphylaxis. Some GH secretagogues show reduced GH response with continuous long-term use. Whether this affects ipamorelin specifically, and to what degree, is not well-characterised in published literature.

Decision rule: ipamorelin has a well-characterised selectivity profile (the cleanest of any GH secretagogue) supported by quality preclinical data. Its practical limitation is the gap between the strong mechanistic/pharmacological rationale and the relative absence of large-scale human clinical trials. Positioning should reflect this evidence level honestly.

Verdict

Ipamorelin is the most selective growth hormone secretagogue characterised in the published literature — a compound that stimulates robust GH release through the ghrelin receptor pathway without the cortisol, appetite, prolactin, and aldosterone effects seen with earlier GH secretagogues like GHRP-2 and GHRP-6.[1]

Its selectivity profile makes it the cleanest GH secretagogue for contexts where avoiding hormonal side effects matters — particularly recovery and sleep support (no cortisol disruption), body composition management (no appetite stimulation), and combination use with GHRH analogs (complementary rather than overlapping pathway).[1][2][3]

The honest limitation: ipamorelin’s evidence base is predominantly preclinical. The selectivity data is well-established, but dedicated human clinical trials for body composition, recovery, or performance outcomes are lacking. Users should understand they are working with strong pharmacological rationale and established selectivity data rather than large-scale clinical proof.

For navigation, map this profile to Recovery & Sleep, Muscle Growth, Fat Loss & Recomp, and Hormonal Support. Pressure-test with Ipamorelin vs Sermorelin, CJC-1295 vs Ipamorelin, Ipamorelin vs Tesamorelin, and Ipamorelin vs MK-677, and cross-reference with GHRP-2 for the less-selective GH secretagogue comparison.

FAQ

What is ipamorelin?

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue that stimulates GH release by activating the ghrelin receptor (GHS-R1a). It is described as “the first selective growth hormone secretagogue” because it elevates GH without significantly affecting cortisol, ACTH, prolactin, or aldosterone. It is not FDA-approved and remains investigational.[1]

What does ipamorelin peptide do?

Ipamorelin activates ghrelin receptors on pituitary somatotroph cells, triggering pulsatile growth hormone release. This elevated GH drives IGF-1 production, which supports tissue repair, recovery, body composition (lean mass maintenance, fat mobilisation), bone health, and sleep-linked recovery processes. Its key distinction is achieving these GH effects without raising cortisol or stimulating appetite.[1][2]

What are ipamorelin benefits?

Key benefits include selective GH release without cortisol/appetite/prolactin elevation, recovery and sleep quality support through nocturnal GH amplification, body composition support, bone health enhancement, and complementarity with GHRH-pathway peptides (CJC-1295, sermorelin). The selectivity profile makes it the cleanest GH secretagogue available.[1][3][4]

What are ipamorelin side effects?

Common side effects include injection site reactions, transient flushing, headache, mild water retention, and occasional tingling. Notably, ipamorelin does NOT significantly elevate cortisol, stimulate appetite, or raise prolactin — side effects common with other GH secretagogues like GHRP-2 and GHRP-6. Overall safety profile is considered acceptable based on available data.[1][3]

Ipamorelin dose and ipamorelin dosage: why not listed here?

This page is informational only and does not provide dosing protocols. Ipamorelin is an investigational compound not approved for any indication. This profile focuses on mechanism context, evidence quality, and risk-aware interpretation.

Ipamorelin CJC-1295: why are they often combined?

They stimulate GH through completely different receptor pathways: ipamorelin via GHS-R1a (ghrelin receptor), CJC-1295 via the GHRH receptor. Dual-pathway stimulation is theorised to produce synergistic GH release greater than either alone. The combination is widely used but lacks dedicated clinical combination trials. See CJC-1295 vs Ipamorelin.[2][7]

Ipamorelin vs sermorelin: which is better?

“Better” depends on priorities. Ipamorelin is more selective (no cortisol/appetite effects) with a longer half-life (~2h vs ~15min). Sermorelin has a historical FDA approval and longer clinical safety record. They work through different receptors and can theoretically be combined. See Ipamorelin vs Sermorelin for the full comparison.[1]

Is ipamorelin FDA approved?

No. Ipamorelin has never been FDA-approved for any indication. It remains an investigational compound. Unlike sermorelin (historical Geref® approval) and tesamorelin (current Egrifta® approval), ipamorelin has not gone through the regulatory approval process.[1][3]

How long does ipamorelin take to work?

GH elevation occurs within 15-30 minutes of injection. IGF-1 increases develop over days. Recovery and body composition improvements typically become noticeable over 4-8 weeks with consistent use. Judge results by multi-week trends in recovery quality and body composition rather than single-day impressions.

Does ipamorelin stimulate appetite?

Minimally, if at all. This is one of ipamorelin’s key advantages over other GH secretagogues. GHRP-6 strongly stimulates appetite (via ghrelin pathway activation), while ipamorelin achieves comparable GH release with minimal appetite effects. This makes it more practical for body composition and fat loss contexts.[1]

Can ipamorelin be used with other peptides?

Ipamorelin is commonly discussed in combination with GHRH-pathway peptides (CJC-1295, sermorelin) based on the dual-receptor-pathway synergy rationale. The compounds target different receptors on the same pituitary cell type, making them mechanistically complementary. However, dedicated clinical combination studies are limited.[2][7]

What should be tracked when evaluating ipamorelin?

Recovery quality upon waking, training readiness between sessions, sleep quality impressions, body composition trends (ideally via DEXA or calibrated measurements), and overall energy levels. Track across 4+ week blocks with controlled training and nutrition. Single-day assessments are unreliable due to many confounding variables.

References

1. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PMID: 9849822.
2. Ahnfelt-Rønne I, et al. Do growth hormone-releasing peptides act as ghrelin secretagogues? Endocrine. 2001;14(1):133-135. PMID: 11322495.
3. Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018;6(1):45-53. PMID: 28400207.
4. Johansen PB, et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res. 1999;9(2):106-113. PMID: 10373343.
5. Andersen NB, et al. The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Growth Horm IGF Res. 2001;11(5):266-272. PMID: 11735244.
6. Svensson J, et al. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. J Endocrinol. 2000;165(3):569-577. PMID: 10828840.
7. Merriam GR, et al. Growth hormone-releasing hormone and growth hormone secretagogues in normal aging. Endocrine. 2003;22(1):41-48. PMID: 14610297.
8. Sinha DK, et al. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol. 2020;9(Suppl 2):S149-S159. PMID: 32257855.
9. Jessup SK, et al. Blockade of endogenous growth hormone-releasing hormone receptors dissociates nocturnal growth hormone secretion and slow-wave sleep. Eur J Endocrinol. 2004;151(5):561-566. PMID: 15538933.
10. Sattler FR. Growth hormone in the aging male. Best Pract Res Clin Endocrinol Metab. 2013;27(4):541-555. PMID: 24054930.
11. Mayfield CK, et al. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. Am J Sports Med. 2026;54(1):223-229. PMID: 41476424.